AD/PD 2024 | Exploring the cognitive impact of BACE1 inhibition for Alzheimer’s disease

Robert Vassar, PhD, Feinberg School of Medicine, Northwestern University, Chicago, IL, summarizes the adverse impact on cognition elicited by β-site amyloid precursor protein (APP) cleaving enzyme 1 (BACE1) inhibition in patients with Alzheimer’s dementia during Phase III trials. As BACE1 cleaves many cellular substrates other than APP, Dr Vassar highlights that the inhibition of cleavage of an alternative substrate may be responsible for the cognitive worsening. Additionally, BACE1 inhibition unexpectedly resulted in patients experiencing disruption to sleep, insomnia, and vivid dreams, which may have impacted cognition. This interview took place at the AD/PD™ 2024 congress in Lisbon, Portugal.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.